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AbstrAct
Tremendous progress in basic and clinical research has 
completely revolutionised the management of advanced 
melanoma, and this dramatic development is still ongoing. 
In this environment, state-of-the-art patient care is a major 
challenge. We describe how patient-centred medicine is 
organised in a leading referral centre that is also involved 
in early and late clinical trials and is part of a worldwide 
network for translational research.
A short look bACk
Treatment of melanoma has dramatically 
evolved over the last decade. Overseeing 
more than 3000 patients between 1995 and 
2019 and witnessing the clash of the Gordon 
node with ipilimumab (ipi)1 and vemurafenib 
(vemu) in 2010/2011,2 I must confess that I 
had never expected this explosion of thera-
peutic possibilities. Before 2000, the brave 
and persistent community of melanoma 
researchers─basic and clinical, or both─have 
investigated every glimpse of hope, without 
any clear success.
During these desperate years of clinical 
research, many clinical scientists involved in 
melanoma trials have smelt that basic science 
achieves major breakthroughs, especially in 
the field of immunology and molecular cancer 
biology. Nobel Prize–winning researchers 
explored the rules to control the T cells and 
its relevance in autoimmunity. Subsequently, 
it became obvious that cancers high check 
these mechanisms to avoid powerful immune 
rejection mechanism. Therefore, a new 
promising treatment paradigm was born that 
was carefully and pertinently investigated, 
resulting in the development of checkpoint 
inhibiting monoclonal ab.3
Insights in the dysregulated wiring of signal-
ling pathways in cancers have suspected the 
mitogen-activated-protein-kinase (MAPK) 
pathway to be essential in melanoma growth 
and survival. Another promising target 
arises. It was the merit of sophisticated phar-
macological fine-tuning to create clinically 
useful small molecules inhibiting the MAPK 
pathway.
I am well aware of these circumstances and 
thankful that my patients with melanoma 
were among the first patients with cancer who 
profited from this research activity. Conse-
quently, I am a strong believer that basic 
researchers will contribute to efficient thera-
pies in the near future. I therefore use every 
opportunity to encourage research teams to 
focus on skin cancers with the promise to 
provide human samples from our biobank.4
PrinCiPles of melAnomA PAtient CAre in An 
ACAdemiC setting
‘The patient is the focus of treatment’ sounds like 
a self-evident statement─however, it presents 
the challenge of the first 60 min with a newly 
referred patient to understand her/his indi-
vidual ideas, social situation,4 goals as well as 
disease perception and expectations. On the 
other side, we need to explain our vision on 
the treatment plan and our commitment to 
apply the most promising regimen. We aim to 
contribute improving the therapeutic options 
but also our engagement in basic research. 
At the end, we wish to establish an open and 
reasonable relationship including regular 
skin examinations that facilitates an honest 
cooperation driven by serious communica-
tion. This is in general supposed to be rather 
direct and transparent with full access to all 
clinical data of the patient and our treatment 
algorithms (figure 1) to align the patient’s 
perspective with the medical outlook. This 
endeavour is supported by educated so-called 
skin cancer nurses that repeat and re-explain 
medical information in the context of the 
social situation.
Our treatment strategy considers the latest knowl-
edge and interdisciplinary expertise.5 6 Since estab-
lished guidelines typically take time to be 
updated, our team must participate in various 
international cancer conferences and special-
ised melanoma meetings and digest the trial 
results. More than 1 year before the approval 
of the recent adjuvant therapies, adjuvant 
dabrafenib/trametinib (dab/tra), nivolumab 
(nivo) and pembrolizumab (pembro) had 
substituted extensive surgery or irradiation 
therapy for locoregional lymph node metas-
tases. Another example is the treatment of 
brain met patients: The preferred use of ipi/
nivo as first line alone7 or in combination 
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Figure 1 Staging and treatment algorithm for cutaneous melanoma as used in the Skin Cancer Center Zürich. CLND, 
complete lymph node dissection; FNA, fine needle aspiration; H&P, history and physical examination; LN, lymph node; mets, 
metastases; SLNB, sentinel lymph node biopsy; SM, safety margin; WLE, wide local expansion.
* Decision not the perform SLNB may be based on significant patient comorbidities, patient preference or other factors, in 
which case follow-up with regional basin US may be considered.
**PET CT for Breslow > 4mm.
with stereotactic radiotherapy was introduced within days 
after the presentation of the respective clinical trials. 
Whenever promising biomarkers are available, we aim 
to present them at our interdisciplinary tumour board. 
In order to decide the therapeutic strategy for a patient, 
it is essential to access medical information directly; all 
relevant images are presented and important routine 
laboratory tests such as LDH must be available. Today, 
we routinely reassess pathological diagnoses from other 
institutes and investigate a wide spectrum of molecular 
alteration including the mutational profile of the most 
important melanoma-associated genetic alterations such 
as mutations in oncogenes, tumour suppressors, muta-
tional load and so on.
Clinical trials are preferred treatment options integrated in 
the treatment plan. Our centre has extensive experience in 
clinical research. We have been involved in various phase 
I and phase III clinical trials, which led to the establish-
ment of targeted therapy (TT) and immunotherapy (IT) 
for stage III and IV metastatic melanoma.
Today, a number of prospective randomised trials 
are available which are important options for daily 
patient care are recommended by our interdisciplinary 
tumour board. In the adjuvant setting, we participate in 
a placebo-controlled clinical trial investigating pembro 
in high-risk patients without lymph node involvement 
(KEYNOTE 716 study—Adjuvant therapy with pembroli-
zumab vs placebo in resected high-risk stage II melanoma, 
a randomized, double-blind phase 3 study) (see figure 1).
Combination IT and combination TT are the estab-
lished first treatment options for metastatic melanoma. 
However, in BRAF mutant patients, we do not yet under-
stand whether sequence of the two treatment options 
matters, and if it would, in which patient population. 
Therefore, we are investigating three different options 
in a randomised multicentre clinical trial (SECOMBIT, 
a three-arm prospective, randomised phase II study 
to evaluate the best sequential approach with combo 
immunotherapy (ipilimumab/nivolumab) and combo 
target therapy (encorafenib/binietinib) in patients with 
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metastatic melanoma and BRAF mutation). In another 
trial, we had also investigated triple therapy using a PD-1 
monoclonal antibody (mab) spartalizumab combined 
with combination targeted therapy dab/tra.
Education must be part of our daily work. We often welcome 
students and visitors from the whole world in the context 
of preceptorships and individuals such as physicians or 
nurses who are interested to be trained in dermato-on-
cology. Our tumour board is well attended by experi-
enced physicians from the field of dermatology, oncology, 
ENT, plastic surgery, radio-oncology, neurosurgery and 
pathology and regularly includes short educational 
presentations.
treAtment deCisions—from stAge i to stAge iV
Patients with low-risk primary melanoma (pT1a) are 
treated by non-disfiguring surgery, do not get imaging 
procedures and are typically followed by dermatologists 
in private offices lifelong.8
Sentinel lymph node biopsy (SLNB) is suggested to 
patients who are capable and motivated to undergo 
adjuvant therapy and a 5-year period of regular imaging 
procedures.
SLNB is the key for the next treatment and follow-up 
consequences, and therefore undergoes strict quality 
control.4 The exact results of the primary tumour and 
the dimensions of the tumour load in the sentinel (SN) is 
essential to estimate the risk for relapse.9
The new American Joint Committee on Cancer classi-
fication (eighth version) is very helpful for defining the 
precise individual prognosis. During the discussion with 
the patient, the risk:benefit ratio is carefully analysed. 
In the context of anti-PD-1 immunotherapy, we always 
mention the low risk (approximately 1%) for devel-
oping lifelong damages that would necessitate ongoing 
drug therapy such as diabetes or hypothyroidism. In our 
point of view, immunotherapy and combination targeted 
therapy are reasonable options, nevertheless.
The available data for adjuvant TT10 are more mature 
and include overall survival (OS) estimations.
Immunotherapy with nivo11 and pembro12 has only 
demonstrated effects on relapse-free survival, but its 
impact on OS can be delineated from the outcome in 
stage IV. In general, adjuvant IT is preferred in most 
patients.
This applies also for stage IV patients with a good 
performance status and normal LDH serum levels. These 
patients receive TT only if they suffer from a symptomatic 
metastatic disease including painful liver, bone or brain 
metastases.
As mentioned, large clinical trials supported by trans-
lational research are in general the preferred options. 
Whenever feasible, tumour material, blood and stool are 
collected and stored in our biobank. According to the 
trial protocols, treatment outcome is monitored by blood 
tests including LDH and S100 monthly and by imaging, 
mostly PET/CT quarterly. In case of mixed response or 
monolesional or oligo-lesional progress, associated with 
clinically meaningful disease control, the addition of 
surgery or irradiation therapy is considered.
Interdisciplinary management of brain metastases 
is challenging because they affect the quality of life in 
early stages and frequently cause death. Therefore, these 
patients need special care in specialised referral centres.5 8
Recent studies confirmed that the preferred systemic 
treatments TT and IT can be safely and efficiently 
applied in patients with brain metastasis (BM). Thus, four 
different treatment modalities may be used depending 
on the individual needs: neurosurgery, stereotactic radio-
surgery (SRS), TT with BRAFi and MEKi combination 
and immunotherapies. Whole brain radiation therapy 
(WBRT) should be avoided whenever possible.13
Dab/tra combo therapy was investigated in a prospec-
tive multicentre, multicohort, open-label, phase II clin-
ical trial in patients with good performance status. The 
response rate (RR) of 50% in BM is similar to the RR 
in other organ sites. However, PFS (median 6 months) 
seems to be shorter.
Ipi/nivo has demonstrated a RR of 50% in patients with 
asymptomatic BM with reasonable response duration. 
However, the inclusion criteria in these trials are strict 
and resulted in a selection of patients with low central 
nervous system tumour burden. These results suggest ipi/
nivo as the preferred first-line option also in BRAF-mu-
tated patients with asymptomatic BM.7 14
Since simultaneous use of multiple sessions of SRS is 
feasible in parallel to IT or TT systemic therapies, close 
disease monitoring by MRIs is recommended in order to 
add SRS if indicated.
Patients with brain metastases, whose local therapy had 
failed, and patients with neurological symptoms using 
dexamethasone or with leptomeningeal disease infre-
quently respond to ipi/nivo. Therefore, this population 
can be treated locally with irradiation. In case of leptome-
ningeal or very extensive disease, WBRT can be applied 
and even combined with systemic treatments such as hTT 
if BRAF mutant or temozolamid if wildtype. Nevertheless, 
the prognosis of this population is extremely poor.
After failure of systemic therapies with impact on 
survival, clinical trials with preferentially well-tolerated 
medications—see pasitreotide as an example15—or 
chemotherapy with taxane or platin derivates are ultima 
ratio possibilities, and a palliative care strategy needs to be 
tailored for the individual patient.
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